Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib versus placebo with ado-trastuzumab emtansine in advanced or metastatic HER2-positive breast cancer
NL-OMON59280Phase 3Completed
- Sponsor
- Seagen Inc.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Tucatinib + ado-trastuzumab emtansine with Placebo + ado-trastuzumab emtansine (2 arms). Primary endpoint: Progression-free survival. Started Jun 2021; status: completed.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON59280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59280.